Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...

The clearance shores up the competitive position for Omvoh (mirikizumab) in the increasingly competitive inflammatory bowel disease ... (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). In ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease ... Johnson's Tremfya (guselkumab), and ...

The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.

3 “The results from the Phase 3 studies demonstrate guselkumab has the potential to become the only IL-23 inhibitor to offer both SC and IV induction options for Crohn’s disease”, said Mark Graham, ...

Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab ... to severely active ulcerative colitis, and Crohn’s disease. Johnson & Johnson holds exclusive worldwide ...

for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

FDA Approves Losartan Oral Suspension Arbli Furoscix (furosemid injection) Loop diuretic Treatment of edema in patients with chronic kidney disease, including nephrotic syndrome. Wearable ...